Loading stock data…
ATRC
$29.02+0.91 (+3.24%)
Market ClosedLast close May 1
AtriCure, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AtriCure, Inc. in the Healthcare sector is trading at $29.02. The stock is currently near its 52-week low of $26.62, remaining 16.1% below its 200-day moving average. Technical signals show neutral RSI of 52 and bullish MACD crossover, explaining why ATRC maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.02
Potential Upside
5%
Whystock Fair Value$30.47
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.40B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.43
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-7.39%
Volume
Today's trading volume
938,596
Recent News
Assessing AtriCure (ATRC) Valuation After Prolonged Share Price Weakness
Event overview and recent share performance AtriCure (ATRC) has been drawing attention after a period of weak share performance, with the stock showing a 3% decline over the past month and a 32% decline over the past 3 months. For investors, that price pressure sits against a backdrop of annual revenue of US$534.5 million and an annual net loss of US$11.4 million. This raises questions about how the current valuation lines up with the underlying business. See our latest analysis for...
AdaptHealth (AHCO) Surges 10.7%: Is This an Indication of Further Gains?
AdaptHealth (AHCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.